These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18327981)

  • 1. Emergence of an NNRTI resistance mutation Y181C in an HIV-infected NNRTI-naive patient.
    Magiorkinis E; Paraskevis D; Sambatakou H; Gargalianos P; Haida C; Vassilakis A; Hatzakis A
    AIDS Res Hum Retroviruses; 2008 Mar; 24(3):413-5. PubMed ID: 18327981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.
    Guo W; Han J; Zhuang D; Liu S; Liu Y; Li L; Li H; Bao Z; Wang F; Li J
    Virol J; 2015 Nov; 12():187. PubMed ID: 26578099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).
    Descamps D; Joly V; Flandre P; Peytavin G; Meiffrédy V; Delarue S; Lastère S; Aboulker JP; Yeni P; Brun-Vézinet F
    J Clin Virol; 2005 Jun; 33(2):99-103. PubMed ID: 15911424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.
    de Baar MP; Janssens W; de Ronde A; Fransen K; Colebunders R; Kestens L; van der Groen G; Goudsmit J
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1385-94. PubMed ID: 11018858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections.
    Kuse N; Rahman MA; Murakoshi H; Tran GV; Chikata T; Koyanagi M; Nguyen KV; Gatanaga H; Oka S; Takiguchi M
    J Virol; 2015 Jul; 89(14):7363-72. PubMed ID: 25972553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
    Liu J; Yue J; Wu S; Yan Y
    Arch Virol; 2007; 152(10):1799-805. PubMed ID: 17619115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
    Reuman EC; Rhee SY; Holmes SP; Shafer RW
    J Antimicrob Chemother; 2010 Jul; 65(7):1477-85. PubMed ID: 20462946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme.
    Bellocchi MC; Forbici F; Palombi L; Gori C; Coelho E; Svicher V; D'Arrigo R; Emberti-Gialloreti L; Ceffa S; Erba F; Marazzi MC; Silberstein FC; Perno CF
    J Med Virol; 2005 Aug; 76(4):452-8. PubMed ID: 15977236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda.
    Troyer RM; Lalonde MS; Fraundorf E; Demers KR; Kyeyune F; Mugyenyi P; Syed A; Whalen CC; Bajunirwe F; Arts EJ
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):235-50. PubMed ID: 18284323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.
    Saracino A; Monno L; Scudeller L; Cibelli DC; Tartaglia A; Punzi G; Torti C; Lo Caputo S; Mazzotta F; Scotto G; Carosi G; Angarano G
    J Med Virol; 2006 Jan; 78(1):9-17. PubMed ID: 16299731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China].
    Han XX; Zhang M; Cui WG; Liu BG; Wang Yn; Zhang ZN; Liu J; Geng WQ; Diao YY; Dai D; Jiang YJ; Shang H
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):760-4. PubMed ID: 15949383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1.
    Richard N; Juntilla M; Abraha A; Demers K; Paxinos E; Galovich J; Petropoulos C; Whalen CC; Kyeyune F; Atwine D; Kityo C; Mugyenyi P; Arts EJ
    AIDS Res Hum Retroviruses; 2004 Apr; 20(4):355-64. PubMed ID: 15157354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphism and drug selected mutations of reverse transcriptase gene in 102 HIV-1 infected patients living in China.
    Liu L; Lu HZ; Henry M; Tamalet C
    J Med Virol; 2007 Oct; 79(10):1593-9. PubMed ID: 17705165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.
    Ibe S; Sugiura W
    Future Microbiol; 2011 Mar; 6(3):295-315. PubMed ID: 21449841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine.
    Suzuki K; Kaufmann GR; Mukaide M; Cunningham P; Harris C; Leas L; Kondo M; Imai M; Pett SL; Finlayson R; Zaunders J; Kelleher A; Cooper DA
    AIDS Res Hum Retroviruses; 2001 Sep; 17(13):1293-6. PubMed ID: 11559430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART.
    Paolucci S; Baldanti F; Maserati R; Castelli F; Suter F; Maggiolo F; Pan A; Gerna G
    Antiviral Res; 2000 Feb; 45(2):101-14. PubMed ID: 10809019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance-associated mutations in HIV-1 among patients failing first-line antiretroviral therapy.
    Saini S; Bhalla P; Gautam H; Baveja UK; Pasha ST; Dewan R
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(3):203-9. PubMed ID: 21990611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.